Prelude

Nonprofits from Inception Fertility and Caden Lane Team Up to Expand Financial Accessibility to Fertility Care

Retrieved on: 
金曜日, 4月 26, 2024
Education, Hope, PGT, Infertility, Partnership, Research, Parent, IVF, ART, Family, Patient, Child, Diagnosis, Prelude, Inception, Birth control

HOUSTON, April 26, 2024 /PRNewswire/ -- The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility Awareness Week (April 21-27, 2024), this partnership aims to raise awareness, offset treatment costs, and support research for more affordable fertility care options.

Key Points: 
  • Launching during National Infertility Awareness Week (April 21-27, 2024), this partnership aims to raise awareness, offset treatment costs, and support research for more affordable fertility care options.
  • The organization was started by TJ Farnsworth, the founder and CEO of Inception Fertility™, and his wife Margaret Farnsworth, who successfully conceived their first child, Wyatt, through IVF.
  • The Conceive Fertility Foundation is the nonprofit arm of Caden Lane , a direct-to-consumer lifestyle brand of baby products focused around the birth of a child.
  • Katy Mimari, CEO of Caden Lane, launched The Conceive Fertility Foundation after her own experience with infertility and understanding the financial barriers that prevent some aspiring parents from building their families.

Prelude and Loyal: Collaborating to Extend Canine Lifespans

Retrieved on: 
金曜日, 4月 19, 2024
Data management, Health, Dog, Clinical data management, Prelude, Partnership, Longevity, Loyal, Pet, EDC, Pharmaceutical industry

The growing rates of canine ownership and the rising demand for solutions to improve the health of dogs have highlighted the need for innovation within the animal health industry.

Key Points: 
  • The growing rates of canine ownership and the rising demand for solutions to improve the health of dogs have highlighted the need for innovation within the animal health industry.
  • Prelude's flexible EDC system and mobile ePRO app will serve as invaluable tools in supporting Loyal's mission to extend the lives and improve the health of dogs.
  • Together, we will advance canine healthcare and make a lasting impact on our pets."
  • "Our partnership with Prelude is pivotal in executing clinical studies with a high standard, thus helping us to deliver on our mission of more, healthier years with the dogs we love."

The Prelude Network Announces 10 of its Clinics Have Been Named America's Best Fertility Clinics

Retrieved on: 
木曜日, 4月 18, 2024
Fertility, Infertility, CDC, Science, Patient, Physician, Patient satisfaction, Prelude, Reproductive medicine, Birth control

HOUSTON, April 18, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest provider of comprehensive fertility services and clinics across North America, announces today nine of its clinics have been named an America's Best Fertility Clinic in 2024.

Key Points: 
  • Presented by Newsweek, America's Best Fertility Clinics 2024 ranks the top 125 fertility clinics nationwide based on surveys, quality metrics, accreditation data, and patient satisfaction
    HOUSTON, April 18, 2024 /PRNewswire/ -- The Prelude Network ® (Prelude), the largest provider of comprehensive fertility services and clinics across North America, announces today nine of its clinics have been named an America's Best Fertility Clinic in 2024.
  • Presented by Newsweek, the America's Best Fertility Clinics 2024 ranking lists the top 125 fertility clinics as defined by the CDC (Centers for Disease Control and Prevention).
  • With global researcher Statista, over 3,000 physicians and other fertility medicine professionals were surveyed, including reproductive endocrinologists, infertility specialists, obstetricians/gynecologists working in and referring patients to fertility clinics, as well as other medical professionals (e.g., registered nurses, laboratory assistants) and fertility clinic administrators/managers working in fertility clinics, to assess confidence in their assessment of the fertility clinics, which was used to determine individual weights for the recommendations.
  • Other criteria that for America's Best Fertility Clinics 2024 award include:
    Quality Metrics: Assisted Reproductive Technology metrics with a focus on indicators relevant to fertility clinics published by CDC were analyzed.

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Retrieved on: 
火曜日, 4月 9, 2024
Breast cancer, SMARCA4, MCL, Generation, Prelude, CDK2, CLL, NSCLC, Patient, SMARCA2, Selective estrogen receptor degrader, BCL2, Cancer, AACR, CRC, BTK, CDK9, DLBCL, Pharmaceutical industry

WILMINGTON, Del., April 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.

Key Points: 
  • Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
    Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC
    WILMINGTON, Del., April 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.
  • “These presentations demonstrate our core competencies in medicinal chemistry and cancer biology to optimize and deliver compounds to the clinic with the potential to succeed as differentiated first- and/or best-in-class new therapies,” said Andrew Combs, Ph.D., Chief Chemistry Officer at Prelude Therapeutics.
  • Peggy Scherle, Ph.D., Chief Scientific Officer at Prelude, stated, “Advancement of our second highly selective SMARCA2 degrader strengthens Prelude’s leadership position in the emerging use of SMARCA2 protein degradation as a potential treatment option for underserved patients with cancer.
  • With both a first-in-class IV SMARCA2 degrader, PRT3789, in Phase 1 clinical development and now our oral SMARCA2 degrader, PRT7732, expected to enter the clinic later this year, we believe these distinct modalities may offer new therapies for patients with SMARCA4 mutations.”
    Details on the poster presentations are as follows:
    Identified potent, selective, well-tolerated and orally bioavailable SMARCA2 degrader, PRT7732
    PRT7732 exhibits >3000-fold selectivity for SMARCA2 over SMARCA4, with low nanomolar potency in cell based assays
    Title: PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies
    PRT2527 is efficacious as monotherapy in preclinical models of DLBCL, CLL and MCL, and combines with both BTK and BCL2 inhibition to improve depth and duration of responses
    Title: The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination with Other Targeted Therapies in Preclinical Models of Breast Cancer, CRC and NSCLC
    Next generation CDK4/6 inhibitor, PRT3645, demonstrates preclinical synergy with SERDs, as well as MEK1/2 and CDK2 inhibition

Prelude Selected by Lemonade to Help Fortify Defenses

Retrieved on: 
水曜日, 4月 3, 2024
Professional Services, Business, Security, Technology, Software, Networks, Microsoft, Organization, Prelude, Insight Partners, XDR, Endpoint, Environment, Intelligence, Partnership, River, Knowledge, Policy, Martin Herem, Mitre Corporation, SentinelOne, Insurance, CrowdStrike, Microsoft Defender Antivirus, Engineering, Sequoia Capital, Risk management

Prelude Security, the company pioneering production-scale detection and response testing, today announced that Lemonade, Inc. (NYSE: LMND), has selected Prelude Detect to fortify their endpoint and server workload security.

Key Points: 
  • Prelude Security, the company pioneering production-scale detection and response testing, today announced that Lemonade, Inc. (NYSE: LMND), has selected Prelude Detect to fortify their endpoint and server workload security.
  • To provide assurance about the state of their security posture, Lemonade deployed Prelude Detect across their production environment, running alongside their CrowdStrike-protected endpoints.
  • Lemonade vetted other solutions but ultimately selected Prelude Detect because of its unique partnership with CrowdStrike, which enables Lemonade to quickly find and fix protection gaps with custom CrowdStrike indicators of attack (IOAs) generated by Prelude Detect.
  • Prelude Detect transforms threat intelligence into validated protections so organizations can know with certainty that their defenses will protect them against the latest threats.

Quaise Energy Raises $21 Million to Accelerate Terawatt-Scale Deep Geothermal Energy

Retrieved on: 
火曜日, 3月 12, 2024
Environment, Finance, Venture Capital, Other Energy, Oil, Gas, Professional Services, Alternative Energy, Green Technology, Energy, Aircraft, Climate change, Prelude, Oak Ridge National Laboratory, Mineral Resources Limited, Mitsubishi Corporation, MIT, Harvard University, Food industry, Research, University, Carbon, Plasma, Workforce, Investment, Multimedia, Renewable energy

Photo: Quaise Energy

Key Points: 
  • Photo: Quaise Energy
    Deep geothermal is one of the most promising sources to meet the global energy transition at scale by creating more energy with fewer resources.
  • A deep geothermal power plant can create 10x more energy than conventional geothermal, provide 24/7 baseload power, and unlock near-universal access to clean energy on a small land footprint.
  • We believe deep geothermal has great potential to become one of these technologies,” said Toshiaki Nobuhara, General Manager, International Utility Dept.
  • “We are honored and excited to join Quaise in its journey to make deep geothermal a reality.”
    Quaise is uniquely positioned to harness deep geothermal energy worldwide at 3-20 km below the Earth’s surface.

Inception Fertility™ 2024 Annual Physician Summit: A Celebration of Collaboration, Patient Dedication, and Advancements in Fertility Research

Retrieved on: 
木曜日, 3月 14, 2024
Diamond, Health, Prelude, Organon, Learning, Merck Serono, Ferring Pharmaceuticals, Physician, Patient, Mental health, Patient experience, Reproductive medicine, Fertility, Labcorp, Inception, The Cooper Companies, Summit, Family, Parent, Nursing

HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.

Key Points: 
  • Global fertility leader's annual summit brings together physicians, team members across Inception's expansive family of brands
    HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility ™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.
  • This included two full days of learning, team building, collaborating, and the field of reproductive medicine.
  • Panel sessions covered topics related to mental health in fertility care, groundbreaking research studies, and using technology to drive the patient and employee experience, among others.
  • The 2024 Patient Experience Awards included the Patient Experience Outstanding Practice Award, Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, and Patient Experience Tenet Leaders Awards.

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Retrieved on: 
木曜日, 2月 15, 2024
Therapy, NSCLC, Research, Docetaxel, Toxicity, AML, Research and development, Cancer, Drug development, SMARCA4, Spacecraft, SMARCA2, ADC, Antibody, Safety, Prelude, Pharmacokinetics, Administration, Lymphoid leukemia, Patient, Acute myeloid leukemia, G&A, Mutation, CDK9, IND, Partnership, Pharmaceutical industry

WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.   

Key Points: 
  • “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
  • A second cohort of patients with AML is expected to initiate in the first half of 2024.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
  • The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.

Castle Connolly Names 40 Physicians within The Prelude Network® as 2024 Top Doctors

Retrieved on: 
火曜日, 2月 13, 2024
Fertility preservation, IUI, Education, Reproductive medicine, Physician, Dream, IVF, Parent, Pleasure, Castle Connolly Medical, PGT, NYU, Faculty, Prelude, Vitrification, Artificial insemination, NYU Langone Health, Patient, Genetic testing, Nursing

HOUSTON, Feb. 13, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility providers in North America, today celebrates 40 of its physicians across 14 clinics within its expansive network who are named a 2024 Top Doctor by Castle Connolly.

Key Points: 
  • The recognition methodology has been vetted and endorsed by the Castle Connolly Medical Advisory Board .
  • Prelude specialists include innovators in fertility care who have pioneered some of today's most advanced reproductive technologies, including vitrification, fertility preservation, and preimplantation genetic testing (PGT).
  • Dr. Jamie Grifo , Program Director at NYU Langone Fertility and Chief Executive Physician of Inception, was named a 2024 Castle Connolly Top Doctor for the 25th year in a row.
  • "Inception Fertility extends its heartfelt congratulations to our incredible physicians who are so deserving of the Top Doctor recognition," says TJ Farnsworth, Founder and CEO of Inception Fertility.

Praetorian Appoints David Hunt as Vice President of Applied Research

Retrieved on: 
木曜日, 1月 11, 2024
Artificial intelligence, Mandiant, CNE, Research, Complex system, Sequoia, Multimedia, Intelligence, Prelude, Applied science, Government, CNA, Labs, Mitre Corporation, Organization, A.I, Automation, CrowdStrike, Cryptocurrency

AUSTIN, Texas, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Praetorian, a leader in advanced offensive security solutions, is proud to announce the appointment of David Hunt as the new Vice President of Applied Research.

Key Points: 
  • Praetorian is proud to announce the appointment of David Hunt as the new Vice President of Applied Research.
  • AUSTIN, Texas, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Praetorian, a leader in advanced offensive security solutions, is proud to announce the appointment of David Hunt as the new Vice President of Applied Research.
  • In his new role, David will oversee the internal research team, Praetorian Labs, focusing on the development of cutting-edge computer network exploitation (CNE) and computer network attack (CNA) tradecraft.
  • "I'm excited to join Praetorian and work closely with the Labs team," Hunt said.